1.
Acta Pharmaceutica Sinica B
;
(6): 442-455, 2021.
Artículo
en Inglés
| WPRIM
| ID: wpr-881146
RESUMEN
Although different types of drugs are available for postmenopausal osteoporosis, the limitations of the current therapies including drug resistances and adverse effects require identification of novel anti-osteoporosis agents. Here, we defined that norlichexanthone (NOR), a natural product, is a ligand of estrogen receptor-alpha (ER